These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 23774812

  • 1. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
    Brown NJ.
    Nat Rev Nephrol; 2013 Aug; 9(8):459-69. PubMed ID: 23774812
    [Abstract] [Full Text] [Related]

  • 2. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ.
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [Abstract] [Full Text] [Related]

  • 3. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR.
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M, Schiffrin EL.
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone and inflammation.
    Gilbert KC, Brown NJ.
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
    [Abstract] [Full Text] [Related]

  • 6. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K, Kobara M, Hamada J, Yoshifuji Y, Shiraishi T, Tanaka T, Wang J, Toba H, Nakata T.
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [Abstract] [Full Text] [Related]

  • 7. Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
    Tsuji H, Wang W, Sunil J, Shimizu N, Yoshimura K, Uemura H, Peck AB, Khan SR.
    World J Urol; 2016 Jan; 34(1):89-95. PubMed ID: 25981400
    [Abstract] [Full Text] [Related]

  • 8. This is not Dr. Conn's aldosterone anymore.
    Brown NJ.
    Trans Am Clin Climatol Assoc; 2011 Jan; 122():229-43. PubMed ID: 21686229
    [Abstract] [Full Text] [Related]

  • 9. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
    Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ.
    Kidney Int; 2009 May; 75(9):936-44. PubMed ID: 19225557
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone and end-organ damage.
    Brown NJ.
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
    [Abstract] [Full Text] [Related]

  • 11. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
    Kagiyama S, Matsumura K, Goto K, Otsubo T, Iida M.
    Regul Pept; 2010 Feb 25; 160(1-3):133-9. PubMed ID: 19969025
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells.
    Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y.
    Endocrinology; 2008 Mar 25; 149(3):1009-14. PubMed ID: 18079208
    [Abstract] [Full Text] [Related]

  • 13. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V, Cachofeiro V, Balfagon G, Rodicio JL.
    ScientificWorldJournal; 2006 Apr 03; 6():413-24. PubMed ID: 16604252
    [Abstract] [Full Text] [Related]

  • 14. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW.
    Prog Cardiovasc Dis; 2010 Apr 03; 52(5):393-400. PubMed ID: 20226957
    [Abstract] [Full Text] [Related]

  • 15. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
    Huang BS, White RA, Ahmad M, Leenen FH.
    Hypertension; 2013 Sep 03; 62(3):564-71. PubMed ID: 23856493
    [Abstract] [Full Text] [Related]

  • 16. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
    Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T.
    Nephrol Dial Transplant; 2007 May 03; 22(5):1314-22. PubMed ID: 17324946
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aldosterone Effect on Cardiac Structure and Function.
    Al-Hashedi EM, Abdu FA.
    Curr Cardiol Rev; 2024 May 03; 20(4):e290224227534. PubMed ID: 38425104
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
    Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR.
    Am J Physiol Renal Physiol; 2009 May 03; 296(5):F1013-22. PubMed ID: 19261739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.